Healthcare Industry News:  Scios 

Biopharmaceuticals Personnel

 News Release - January 13, 2009

Jennerex Appoints Samantha Miller as Vice President of Corporate Development

SAN FRANCISCO, Jan. 13 -- (Healthcare Sales & Marketing Network) -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biotherapeutics company, is pleased to announce that Samantha Miller has been appointed to the position of Vice President of Corporate Development.

Ms. Miller has over 15 years of biotechnology and pharmaceutical business development experience, and has negotiated, executed and managed numerous global partnerships, as well as regional partnerships in the United States, Europe, Japan and elsewhere. She has been involved in executing over 30 partnerships and licenses, with companies such as GlaxoSmithKline, Eli Lilly, Johnson & Johnson, AstraZeneca, Astellas and others.

Ms. Miller has held senior positions in business development, including the title of Vice President, in various companies including Anesiva, Theravance, Scios Pharmaceuticals, Onyx Pharmaceuticals and Procter & Gamble Pharmaceuticals.

"Samantha is an outstanding addition to our executive management team. As Jennerex continues to report compelling Phase 1 and 2 clinical data from its oncology programs, Samantha joins us at an opportune time for the development of additional strategic partnerships," said David H. Kirn, M.D., President and Chief Executive Officer. "We have clear regulatory pathways to large global cancer markets with multiple products, and Samantha's addition to the Jennerex team further endorses the potential of the Company's product platform," added Dr. Kirn.

Ms. Miller holds a BS in Biochemistry/ Cell Biology from UCSD, and she holds Masters degrees in both Immunology and in Business Administration (MBA) from the University of Rochester.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.


Source: Jennerex

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.